ad image

Parkinson's Disease

1 / 1
Cyrano Therapeutics
Announcement

Cyrano Therapeutics Launches Clinical Study of CYR-064 for Smell Loss (Hyposmia) in Parkinson's Disease Patients.

Cyrano Therapeutics

PR-01-25-NI-32Feb 04, 2025
AbbVie
Announcement

AbbVie Announces Topline Results for the Phase 3 TEMPO-2 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease

AbbVie

PR-12-24-NI-134Dec 11, 2024
Preparing for Growth in Neurodegenerative Treatment Opportunities: How Clinical Teams can Best Position Study Design and Strategy to Reach Study Participants
Neurodegenerative Disease Clinical Trials

Preparing for Growth in Neurodegenerative Treatment Opportunities: How Clinical Teams can Best Position Study Design and Strategy to Reach Study Participants

John Hamlet; Christine Martino, MPM; Sabine Krofczik-Wilhelm, Ph.D.; Alberto Lledó, M.D., Ph.D.

PPD, part of Thermo Fisher Scientific

PAO-09-022-CL-09Sep 27, 2022
Unlocking the Therapeutic Potential of Plant-Inspired Minimum Essential Mixtures
Plant-Inspired Drug Discovery

Unlocking the Therapeutic Potential of Plant-Inspired Minimum Essential Mixtures

Andrea Small-Howard, Ph.D.

Gb Sciences, Inc.

PAO-08-022-CL-01Sep 06, 2022
Gb Sciences, Inc.
Parkinson's Disease Research

Gb Sciences to Begin Dosage Study for Its Novel Parkinson's Disease Formulations at the University of Lethbridge

Gb Sciences, Inc.

PR-M04-22-08Apr 12, 2022
Pioneering Nanocatalysis to Revolutionize Treatments for Neurodegenerative Diseases
Neurodegenerative Diseases

Pioneering Nanocatalysis to Revolutionize Treatments for Neurodegenerative Diseases

Rob Etherington

PAO-01-22-CL-06Mar 12, 2022
Novel Computational Approaches to Parkinson's Disease Drug Development
Parkinsons's Disease

Novel Computational Approaches to Parkinson's Disease Drug Development

Eric Richman

PTV-08-21-CL-002Aug 18, 2021
Leveraging Organoids to Address Neurodegenerative Diseases
Brain Organoids

Leveraging Organoids to Address Neurodegenerative Diseases

OrganoTherapeutics

PAO-04-22-R221-66-400Apr 29, 2021
Changing the Paradigm of Stem Cell Technology
Stem Cells

Changing the Paradigm of Stem Cell Technology

Sandy Solmon

Celavie Biosciences

PAP-Q4-20-CL-008Dec 09, 2020
A Therapeutic Strategy for Neurological Disorders
Drug Repositioning

A Therapeutic Strategy for Neurological Disorders

Franck Mouthon; Mathieu Charvériat, Ph.D.

Theranexus

PAP-Q2-20-CL-016Jul 01, 2020
University of California San Diego
Cell and Gene Therapy

One-time Treatment Generates New Neurons, Eliminates Parkinson's Disease in Mice

University of California San Diego

PR-M06-20-NI-036Jun 30, 2020
U.S. Food & Drug Administration
FDA Approval

FDA Approves New Add-on Drug to Treat Off Episodes in Adults with Parkinson’s disease

U.S. Food & Drug Administration

PR-M08-19-NI-090Aug 30, 2019
University of Houston
Next-Generation Therapy

Smart Brain Stimulators: Next-Gen Parkinson’s Disease Therapy

University of Houston

PR-M07-19-NI-077Jul 30, 2019
New Collaboration Targets Parkinson’s Disease
Collaboration

New Collaboration Targets Parkinson’s Disease

Pharma's Almanac

PAO-M03-19-NI-005Mar 05, 2019
Britannia Pharmaceuticals
Phase 3 Study

Britannia Pharmaceuticals Ltd: Phase 3 TOLEDO Study Shows Apomorphine Infusion Provides Effective Relief of Persistent Motor Fluctuations in Parkinson's Disease

Britannia Pharmaceuticals

PR-M08-18-NI-043Aug 13, 2018
1 / 1